Dynavax Technologies Corporation

NasdaqGS DVAX

Dynavax Technologies Corporation Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.40

Dynavax Technologies Corporation Debt to Equity Ratio is 0.40 for the Trailing 12 Months (TTM) ending September 30, 2024, a -9.67% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Dynavax Technologies Corporation Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.44, a -38.88% change year over year.
  • Dynavax Technologies Corporation Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.72, a -76.55% change year over year.
  • Dynavax Technologies Corporation Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 3.07, a -48.11% change year over year.
  • Dynavax Technologies Corporation Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 5.91, a 25.05% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
NasdaqGS: DVAX

Dynavax Technologies Corporation

CEO Mr. Ryan Spencer
IPO Date Feb. 19, 2004
Location United States
Headquarters 2100 Powell Street
Employees 408
Sector Health Care
Industries
Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

LNTH

Lantheus Holdings, Inc.

USD 92.62

-2.15%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

EBS

Emergent BioSolutions Inc.

USD 9.36

-0.53%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

AQST

Aquestive Therapeutics, Inc.

USD 3.05

-1.93%

StockViz Staff

January 15, 2025

Any question? Send us an email